365telugu.com online news,Mumbai, December 3, 2025: Corona Remedies Limited (CRL), an India-focused branded pharmaceutical formulation company, today announced that its Initial Public Offering (IPO) will open for subscription on Monday, December 8, 2025, and will close on Wednesday, December 10, 2025.
The company has fixed the Price Band for the offer at ₹1,008 to ₹1,062 per Equity Share of face value ₹10 each.
IPO Key DetailsFeatureDetailsBidding PeriodDecember 8 to December 10, 2025Price Band₹1,008 – ₹1,062 per Equity ShareMinimum Bid Quantity14 Equity Shares (and in multiples thereafter)Anchor Investor BiddingFriday, December 5, 2025Offer Size (OFS)Up to ₹6,553.71 million (Offer for Sale)Employee Discount₹54 per Equity ShareListingNSE and BSEThe offer is entirely an Offer for Sale (OFS) aggregating up to ₹6,553.71 million.
The selling shareholders include Promoter Dr. Kirtikumar Laxmidas Mehta (up to ₹1,298.41 million), Promoting Group members, and Investor Selling Shareholders such as Sepia Investments Limited (up to ₹4,046.00 million), Anchor Partners, and Sage Investment Trust.
The Book Running Lead Managers for the Offer are JM Financial Limited, IIFL Capital Services Limited, and Kotak Mahindra Capital Company Limited.
Company Profile and GrowthCorona Remedies is a key player in the Indian branded pharmaceutical market, focusing on therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, and urology.
| Feature | Details |
| Bidding Period | December 8 to December 10, 2025 |
| Price Band | ₹1,008 – ₹1,062 per Equity Share |
| Minimum Bid Quantity | 14 Equity Shares (and in multiples thereafter) |
| Anchor Investor Bidding | Friday, December 5, 2025 |
| Offer Size (OFS) | Up to ₹6,553.71 million (Offer for Sale) |
| Employee Discount | ₹54 per Equity Share |
| Listing | NSE and BSE |
As of June 30, 2025, the company manages a diversified portfolio of 71 brands.According to the CRISIL Intelligence Report, Corona Remedies has demonstrated exceptional growth:Fastest Growing: It was the fastest-growing company among the top 30 in the Indian Pharmaceutical Market (IPM) in terms of domestic sales between the Moving Annual Total (MAT) periods of June 2024 and June 2025.
Second Fastest: It ranked as the second fastest-growing company among the top 30 in the IPM between MAT June 2022 and MAT June 2025.Key Therapeutic Areas Include:Women’s Healthcare: Brands covering the lifecycle from adolescence through post-menopause.
Cardio-Diabeto: Formulations addressing various stages of diabetes, hypertension, and cardiac disorders.
Pain Management: Products in four dosage forms for musculoskeletal spasms and diabetes neuropathy pain, among others.
Urology: Offerings for benign prostatic hyperplasia, overactive bladder, and urinary tract infections.Allocation StructureThe IPO is being made through the Book Building Process.
The allocation will be structured as follows:Qualified Institutional Buyers (QIBs): Not more than 50% of the Net Offer.
Up to 60% of the QIB portion is reserved for Anchor Investors.
Non-Institutional Bidders (NIBs): Not less than 15% of the Net Offer, with specific reservations based on application size.
Retail Individual Bidders (RIBs): Not less than 35% of the Net Offer.
Eligible Employees: A discount of ₹54 per share is offered to employees bidding in the Employee Reservation Portion,